Metraipolis › archive › dc_6d11984e033f

Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and in vivo pharmacokinetic evaluation — Europe PMC PMID:40970085

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40970085
DOI
10.1039/d5na00386e
License (as archived)
solo-consultazione
Archived
2026-11-09T21:34:04.784Z
SHA-256 of the archived text
785a193bb248991da1bf21ba0f938da3e0db9a97d758faad94275ba4bad1443c
Stable URL of this page
https://metraipolis.com/documento/dc_6d11984e033f

How to cite

Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and in vivo pharmacokinetic evaluation — Europe PMC PMID:40970085 — Europe PMC (en), https://europepmc.org/article/MED/40970085 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6d11984e033f (Metraipolis archive dc_6d11984e033f, sha256 785a193bb248991da1bf21ba0f938da3e0db9a97d758faad94275ba4bad1443c)
BibTeX
@misc{dc6d11984e033f,
  title = {Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and in vivo pharmacokinetic evaluation — Europe PMC PMID:40970085},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40970085},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6d11984e033f; sha256 785a193bb248991da1bf21ba0f938da3e0db9a97d758faad94275ba4bad1443c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40970085. Agents can read the archived copy with the MCP tool read_document.